## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STAT
Instruction 1(b).	

## TEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Peoples Oliver P					2. Issuer Name <b>and</b> Ticker or Trading Symbol  YIELD10 BIOSCIENCE, INC. [ YTEN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last)	(Fil	rst) (SCIENCE, INC.	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/01/2019   X Director 10% Owner X Officer (give title below) Pres & CEO															
(Street) WOBUR (City)			)1801 Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									ine) X	orm=	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,					Securities Acquired (A) posed Of (D) (Instr. 3, 4			and 5) Securi Benefi Owned		cially I Following	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	Ownership				
							Code	v	Amount	(/	A) or O)	Price	_   т	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
Common Stock 08/01/2				/2019	:019		P		10,000	1)	A	\$0.9	)2 <sup>(2)</sup>	47,628		D				
Common Stock															18	,246 <sup>(3)</sup>	I	By 401(k) Plan		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code ( 8)		5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr	ative rities ired osed			e	Amount of Securities Underlying Derivative Security (Instr. and 4)		ount nber	t		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. These shares were purchased pursuant to a Rule 10b5-1 buying plan adopted by the reporting person on June 3, 2019.
- 2. Represents the weighted average sales price for the shares purchased. Sales prices for this transaction ranged from \$0.8695 to \$0.9199. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, Yield10 Bioscience, Inc., or a security holder of Yield10 Bioscience, Inc., full information regarding the number of shares purchased at each separate price.
- $3.\ These\ shares\ were\ acquired\ as\ Company\ matching\ contributions\ under\ the\ Yield 10\ Bioscience,\ Inc.\ 401(k)\ Plan.$

/s/ Megan N. Gates, attorney-

\*\* Signature of Reporting Person

in-fact

08/02/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.